Cutler Group LP Theravance Biopharma, Inc. Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 04, 2022	SELL	$8.41 - $10.34 $17,661 - $21,714	-2,100 Closed	0 $0
Q1 2022 Apr 14, 2022	BUY	$8.33 - $12.96 $14,161 - $22,032	1,700 Added 425.0%	2,100 $0
Q4 2021 Jan 18, 2022	SELL	$7.42 - $11.05 $84,588 - $125,970	-11,400 Reduced 96.61%	400 $0
Q3 2021 Oct 26, 2021	BUY	$6.77 - $14.41 $79,886 - $170,038	11,800 New	11,800 $1,000
Q2 2021 Jul 19, 2021	SELL	$14.52 - $22.46 $36,300 - $56,150	-2,500 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$16.57 - $21.08 $41,425 - $52,699	2,500 New	2,500 $4,000
Q2 2020 Jul 22, 2020	SELL	$20.64 - $30.69 $30,960 - $46,035	-1,500 Closed	0 $0
Q1 2020 May 07, 2020	BUY	$17.84 - $31.21 $26,760 - $46,815	1,500 New	1,500 $3,000
Q3 2018 Nov 07, 2018	SELL	$22.83 - $32.67 $114,149 - $163,350	-5,000 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$23.37 - $29.71 $116,850 - $148,550	5,000 New	5,000 $4,000

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $658M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.